BR112018075396A2 - dengue neutralizing antibody for use in a method of preventing and / or treating Zika infection - Google Patents
dengue neutralizing antibody for use in a method of preventing and / or treating Zika infectionInfo
- Publication number
- BR112018075396A2 BR112018075396A2 BR112018075396-3A BR112018075396A BR112018075396A2 BR 112018075396 A2 BR112018075396 A2 BR 112018075396A2 BR 112018075396 A BR112018075396 A BR 112018075396A BR 112018075396 A2 BR112018075396 A2 BR 112018075396A2
- Authority
- BR
- Brazil
- Prior art keywords
- residues
- flaviviruses
- zika
- denv
- virus
- Prior art date
Links
- 208000020329 Zika virus infectious disease Diseases 0.000 title abstract 6
- 208000001490 Dengue Diseases 0.000 title abstract 4
- 206010012310 Dengue fever Diseases 0.000 title abstract 4
- 208000025729 dengue disease Diseases 0.000 title abstract 4
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 241000710831 Flavivirus Species 0.000 abstract 13
- 241000907316 Zika virus Species 0.000 abstract 8
- 239000000539 dimer Substances 0.000 abstract 5
- 239000000178 monomer Substances 0.000 abstract 5
- 241000725619 Dengue virus Species 0.000 abstract 4
- 102000003886 Glycoproteins Human genes 0.000 abstract 4
- 108090000288 Glycoproteins Proteins 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 239000000833 heterodimer Substances 0.000 abstract 2
- 239000000710 homodimer Substances 0.000 abstract 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
- 101100234741 Chlamydomonas reinhardtii pf13 gene Proteins 0.000 abstract 1
- 239000004971 Cross linker Substances 0.000 abstract 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 235000000346 sugar Nutrition 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
- C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
Abstract
trata-se de um epítopo de dímero de envelope (ede) de flavivírus para uso em vacinação de um indivíduo contra um ou mais flavivírus em que o ede é um flavivírus recombinante estabilizado, opcionalmente dímero de ectodomínio e (se) de glicoproteína de envelope de zika e/ou vírus da dengue, em que o dímero é: covalentemente estabilizado com pelo menos uma ligação intercadeia de dissulfeto entre os dois monômeros de se, e/ou não covalentemente estabilizado com a substituição de pelo menos um resíduo de aminoácido na sequência de aminoácidos de pelo menos um monômero de se por pelo menos um aminoácido de cadeia lateral volumoso na interface de dímero ou no ligante de domínio 1 (d1)/domínio 3 (d3) de cada monômero, covalentemente estabilizado com pelo menos um reticulador reativo à sulfidrila entre os dois monômeros de se, e/ou covalentemente estabilizado através da formação como uma cadeia de polipeptídeos única, opcionalmente com uma região de ligante, opcionalmente uma região de ligante rica em serina e glicina, que separa as sequências de se, e/ou covalentemente estabilizado pela ligação dos dois monômeros de se através de açúcares modificados; e/ou, em que o dímero é um homodímero ou heterodímero de polipeptídeos de envelope mutantes e/ou nativos, de qualquer um ou dois dentre denv-1, denv-2, denv-3, denv-4, zika ou outros flavivírus; e em que o um ou mais flavivírus são selecionados a partir de vírus da zika; vírus da zika e vírus da dengue; vírus da zika e outros flavivírus; flavivírus além da dengue. o ede pode ser um homodímero ou heterodímero de polipeptídeos de envelope mutantes e/ou nativos de qualquer um ou dois dentre denv-1, denv-2, denv-3, denv-4 e zika. anticorpo neutralizante isolado ou fragmento de ligação ao antígeno direcionado contra o ede, conforme definido em qualquer uma das reivindicações 1 a 29, em que, opcionalmente, o dito anticorpo ou fragmento do mesmo liga os cinco segmentos de polipeptídeo do ectodomínio e (se) de glicoproteína de vírus da dengue que consistem nos resíduos 67 a 74, resíduos 97 a 106, resíduos 307 a 314, resíduos 148 a 159 e resíduos 243 a 251 ou resíduos correspondentes do ectodomínio e de glicoproteína de vírus da zika ou flavivírus ou que consistem em zika pf13 resíduos 67 a 77, resíduos 97 a 106, resíduos 313 a 315, resíduos 243 a 253, resíduo k373 ou resíduos correspondentes do ectodomínio e de glicoproteína de flavivírus, em que, opcionalmente, a ligação não é afetada pela presença ou ausência de glicano de dengue n153 (zika n154) ou resíduo correspondente, para uso em um método para prevenção e/ou tratamento de infecção por um ou mais flavivírus, em que o um ou mais flavivírus são selecionados a partir de vírus da zika; vírus da zika e vírus da dengue; vírus da zika e outros flavivírus; flavivírus além da dengue.This is a flavivirus envelope dimer (ede) epitope for use in vaccinating an individual against one or more flaviviruses wherein the ede is a stabilized recombinant flavivirus, optionally ectodomain dimer and (if) glycoprotein envelope (s). zika and / or dengue virus, wherein the dimer is: covalently stabilized with at least one disulfide interlinkage bond between the two monomers of se, and / or non-covalently stabilized with the substitution of at least one amino acid residue in the sequence. amino acids of at least one monomer and at least one bulky side chain amino acid at the dimer interface or domain 1 (d1) / domain 3 (d3) linker of each monomer, covalently stabilized with at least one sulfhydryl reactive crosslinker between the two monomers of each other, and / or covalently stabilized by forming as a single polypeptide chain, optionally with a ligand region. and, optionally a serine and glycine-rich linker region, which separates the se sequences and / or covalently stabilized by the binding of the two se monomers via modified sugars; and / or wherein the dimer is a homodimer or heterodimer of native and / or mutant envelope polypeptides of any one or two of denv-1, denv-2, denv-3, denv-4, zika or other flaviviruses; and wherein one or more flaviviruses are selected from Zika virus; Zika virus and dengue virus; Zika virus and other flaviviruses; flaviviruses besides dengue. The ede may be a homodimer or heterodimer of mutant and / or native envelope polypeptides of either one or two of denv-1, denv-2, denv-3, denv-4 and zika. isolated neutralizing antibody or ede-directed antigen-binding fragment as defined in any one of claims 1 to 29, wherein optionally said antibody or fragment thereof binds the five ectodomain and (if) polypeptide segments. dengue virus glycoprotein consisting of residues 67 to 74, residues 97 to 106, residues 307 to 314, residues 148 to 159 and residues 243 to 251 or corresponding residues of ectodomain and glycoprotein of Zika virus or flavivirus or consisting of zika pf13 residues 67 to 77, residues 97 to 106, residues 313 to 315, residues 243 to 253, residues k373 or corresponding ectodomain and flavivirus glycoprotein residues, where optionally binding is not affected by the presence or absence of dengue glycan n153 (zika n154) or corresponding residue, for use in a method for preventing and / or treating infection with one or more flaviviruses, wherein the one or more flaviviruses are selected from Zika virus; Zika virus and dengue virus; Zika virus and other flaviviruses; flaviviruses besides dengue.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1610162.8A GB201610162D0 (en) | 2016-06-10 | 2016-06-10 | Methods |
| GB1610162.8 | 2016-06-10 | ||
| PCT/GB2017/051692 WO2017212291A1 (en) | 2016-06-10 | 2017-06-09 | Neutralising antibody against dengue for use in a method of prevention and/or treatment of zika infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018075396A2 true BR112018075396A2 (en) | 2019-03-19 |
Family
ID=56894660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018075396-3A BR112018075396A2 (en) | 2016-06-10 | 2017-06-09 | dengue neutralizing antibody for use in a method of preventing and / or treating Zika infection |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11111274B2 (en) |
| EP (1) | EP3468591A1 (en) |
| JP (1) | JP2019523647A (en) |
| BR (1) | BR112018075396A2 (en) |
| CA (1) | CA3066488A1 (en) |
| GB (1) | GB201610162D0 (en) |
| MX (1) | MX2018015343A (en) |
| WO (1) | WO2017212291A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009041613A1 (en) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| MX2019001448A (en) | 2016-08-05 | 2019-09-13 | Chugai Pharmaceutical Co Ltd | Composition for prophylaxis or treatment of il-8 related diseases. |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| CN111511395B (en) | 2017-11-03 | 2024-10-15 | 武田疫苗股份有限公司 | Methods for inactivating Zika virus and for determining completeness of inactivation |
| JP2021505549A (en) | 2017-11-30 | 2021-02-18 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | Dika vaccine and immunogenic composition, and how to use them |
| MX2020009296A (en) * | 2018-03-15 | 2020-11-13 | Chugai Pharmaceutical Co Ltd | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use. |
| EP3870208A4 (en) * | 2018-10-26 | 2022-10-26 | New York Blood Center, Inc. | Zika virus immunogenic compositions |
| JP7221995B2 (en) * | 2019-05-28 | 2023-02-14 | チェンマイ・ユニバーシティ | Mature virus-like particles of flaviviruses |
| US20210060152A1 (en) * | 2019-09-03 | 2021-03-04 | National Health Research Institutes | Multiple mosquito-borne flavivirus vaccine and use thereof in inducing neutralizing antibodies |
| JP7471555B2 (en) * | 2020-02-20 | 2024-04-22 | 国立感染症研究所長 | Flavivirus cross-neutralizing antibodies and pharmaceutical compositions |
| WO2023235660A2 (en) * | 2022-05-17 | 2023-12-07 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Flavivirus immunogens and vaccine compositions and methods of using the same |
| WO2024081625A1 (en) * | 2022-10-11 | 2024-04-18 | University Of Maryland, Baltimore | Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2576798C (en) | 2004-07-27 | 2014-09-09 | Gwong-Jen J. Chang | Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use |
| CU23586A1 (en) * | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | METHODS AND PROTEINS FOR THE PROPHLACTIC AND / OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF THE DENGUE VIRUS AND OTHER FLAVIVIRUS |
| GB201413086D0 (en) | 2014-07-23 | 2014-09-03 | Imp Innovations Ltd And Inst Pasteur | Methods |
-
2016
- 2016-06-10 GB GBGB1610162.8A patent/GB201610162D0/en not_active Ceased
-
2017
- 2017-06-09 WO PCT/GB2017/051692 patent/WO2017212291A1/en unknown
- 2017-06-09 EP EP17737013.7A patent/EP3468591A1/en active Pending
- 2017-06-09 JP JP2018564238A patent/JP2019523647A/en active Pending
- 2017-06-09 MX MX2018015343A patent/MX2018015343A/en unknown
- 2017-06-09 BR BR112018075396-3A patent/BR112018075396A2/en unknown
- 2017-06-09 CA CA3066488A patent/CA3066488A1/en active Pending
- 2017-06-09 US US16/308,745 patent/US11111274B2/en active Active
-
2021
- 2021-04-27 US US17/241,884 patent/US11926648B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| GB201610162D0 (en) | 2016-07-27 |
| EP3468591A1 (en) | 2019-04-17 |
| WO2017212291A1 (en) | 2017-12-14 |
| US20210355167A1 (en) | 2021-11-18 |
| MX2018015343A (en) | 2019-11-18 |
| CA3066488A1 (en) | 2017-12-14 |
| US11926648B2 (en) | 2024-03-12 |
| US11111274B2 (en) | 2021-09-07 |
| US20190256560A1 (en) | 2019-08-22 |
| JP2019523647A (en) | 2019-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018075396A2 (en) | dengue neutralizing antibody for use in a method of preventing and / or treating Zika infection | |
| EP4223773A3 (en) | Methods | |
| PE20211272A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
| BR112015032875A2 (en) | derived from glp-1 peptides, and uses thereof | |
| BR112018007318A2 (en) | isolated antibody or antigen binding fragment, pharmaceutical composition, and methods for treating a disease or condition. | |
| BR112016016411A2 (en) | "Fc"-REGION VARIANTS WITH MODIFIED "FcRn" BINDING PROPERTIES | |
| PE20191551A1 (en) | DESIGNED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES | |
| RU2021124437A (en) | CONSTRUCTIONS AIMED AT THE AFP / MHC PEPTIDE COMPLEXES AND THEIR USES | |
| PE20190352A1 (en) | GDF 15 FUSION PROTEINS AND USES OF THEM | |
| CY1119976T1 (en) | Calcitonin Mimics for the Treatment of Diseases and Disorders | |
| PE20221909A1 (en) | ANTIGEN-BINDING MOLECULES COMPRISING A LIGAND TRIMER OF THE TNF FAMILY | |
| BR112017017029A2 (en) | degradable thiolene polymers and methods for their manufacture | |
| BR112013008407A2 (en) | clostridium difficile antigens | |
| BR112018073511A2 (en) | glucagon receptor selective polypeptides and methods of use | |
| BR112018071686A2 (en) | membrane integral protein display in enveloped extracellular poxvirus virions | |
| BR112014024751A2 (en) | clostridium difficile antigens | |
| BR112018007960A2 (en) | conjugate, pcrv protein, immunogenic composition, methods of preparing an immunogenic composition, treating and producing a bioconjugate, polynucleotide, vector, host cell, and, bioconjugate. | |
| BR112015021341A2 (en) | flavivirus neutralizing antibodies and methods of use | |
| BR112018003594A2 (en) | recombinant immunoglobulin heavy chain, antibodies, conjugate production method and conjugates | |
| PE20181956A1 (en) | POLYPEPTIDES THAT INHIBIT CD40L | |
| BR112017017609A2 (en) | fc fusion protein, and pharmaceutical composition. | |
| BR112019003462A2 (en) | fusion protein, polynucleotide, viral vector, pharmaceutical composition, use of a fusion protein, polynucleotide, viral vector or pharmaceutical composition, and method for treating or preventing viral hepatitis b infection or viral hepatitis c infection | |
| BR112016014913A8 (en) | antibody, or an antigen-binding fragment thereof, conjugate, nucleic acid, vector, host cell, pharmaceutical composition, method of preparing an antibody light chain or antigen-binding fragment, and method of preparing a conjugate | |
| JP2014506452A5 (en) | ||
| BR112021026789A2 (en) | Recombinant human sialidases, sialidase fusion proteins and methods of using them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15V | Prolongation of time limit allowed |
Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020 E PORTARIA INPI PR NO 179 DE 11/05/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 31/05/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME. |
|
| B25G | Requested change of headquarter approved |
Owner name: INSTITUT PASTEUR (FR) ; IMPERIAL INNOVATIONS LTD (GB) |
|
| B25A | Requested transfer of rights approved |
Owner name: INSTITUT PASTEUR (FR) ; IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |